These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 27903600)

  • 1. Improved Accuracy of Cefepime Susceptibility Testing for Extended-Spectrum-Beta-Lactamase-Producing Enterobacteriaceae with an On-Demand Digital Dispensing Method.
    Smith KP; Brennan-Krohn T; Weir S; Kirby JE
    J Clin Microbiol; 2017 Feb; 55(2):470-478. PubMed ID: 27903600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007.
    Jean SS; Lee WS; Bai KJ; Lam C; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
    J Microbiol Immunol Infect; 2015 Feb; 48(1):85-91. PubMed ID: 23973410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reevaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for 9 beta-lactams: adjustments of breakpoints for strains producing extended spectrum beta-lactamases.
    Jones RN; Craig WA; Ambrose PG; Dudley MN; Pottumarthy S
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):235-46. PubMed ID: 16105568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reevaluation of the cefepime minimal inhibitory concentrations and disk diffusion test zone diameter relationship for a worldwide collection of Enterobacteriaceae enriched for extended-spectrum beta-lactamase-producing organisms.
    Pottumarthy S; Deshpande LM; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jun; 52(2):95-9. PubMed ID: 15964496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility testing accuracy of a CTX-M-type extended-spectrum beta-lactamase organism-producing population of Enterobacteriaceae: intermethod analysis for 9 beta-lactams.
    Pottumarthy S; Yu Y; Sader HS; Jones RN; Chen M
    Diagn Microbiol Infect Dis; 2005 Oct; 53(2):131-41. PubMed ID: 15939566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of MicroScan WalkAway and Vitek 2 for determination of the susceptibility of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates to cefepime, cefotaxime and ceftazidime.
    Jang W; Park YJ; Park KG; Yu J
    J Antimicrob Chemother; 2013 Oct; 68(10):2282-5. PubMed ID: 23671215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefepime versus extended spectrum β-lactamase-producing Enterobacteriaceae.
    Nogueira Kda S; Daur AV; Reason IT; Gales AC; Costa LM
    Braz J Infect Dis; 2011; 15(2):167-9. PubMed ID: 21503406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.
    Nguyen HM; Shier KL; Graber CJ
    J Antimicrob Chemother; 2014 Apr; 69(4):871-80. PubMed ID: 24265230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of Broth Microdilution MIC and Disk Diffusion Antimicrobial Susceptibility Test Quality Control Ranges for the Combination of Cefepime and the Novel β-Lactamase Inhibitor Enmetazobactam.
    Belley A; Huband MD; Fedler KA; Watters AA; Flamm RK; Shapiro S; Knechtle P
    J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31167844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characterization of extended-spectrum beta-lactamases and its correlation with clinical laboratory standards institute interpretive criteria for disk diffusion susceptibility testing in enterobacteriaceae isolates in Thaialnd.
    Tangkoskul T; Tiengrim S; Onsomang S; Pati N; Aswapokee N; Thamlikitkul V; Chayakulkeeree M
    Southeast Asian J Trop Med Public Health; 2012 Nov; 43(6):1461-9. PubMed ID: 23413710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Thomson KS; Moland ES
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3548-54. PubMed ID: 11709338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consequences of revised CLSI and EUCAST guidelines for antibiotic susceptibility patterns of ESBL- and AmpC β-lactamase-producing clinical Enterobacteriaceae isolates.
    Hombach M; Mouttet B; Bloemberg GV
    J Antimicrob Chemother; 2013 Sep; 68(9):2092-8. PubMed ID: 23633681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.
    Sader HS; Rhomberg PR; Flamm RK; Jones RN; Castanheira M
    J Antimicrob Chemother; 2017 Jun; 72(6):1696-1703. PubMed ID: 28333332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency and epidemiology of extended-spectrum β-lactamase-producing Enterobacteriaceae isolates susceptible to third-generation cephalosporins or to aztreonam.
    Bert F; Bialek-Davenet S; Leflon-Guibout V; Noussair L; Nicolas-Chanoine MH
    Med Mal Infect; 2014 Feb; 44(2):76-8. PubMed ID: 24525113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI screening parameters for the detection of extended-spectrum β-lactamase production in clinical Enterobacteriaceae isolates.
    Polsfuss S; Bloemberg GV; Giger J; Meyer V; Hombach M
    J Antimicrob Chemother; 2012 Jan; 67(1):159-66. PubMed ID: 21972269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasmid-Mediated AmpC β-Lactamase and Underestimation of Extended-Spectrum β-Lactamase in Cefepime-Susceptible Elevated-Ceftazidime-MIC Enterobacteriaceae Isolates.
    Nishimura F; Morinaga Y; Akamatsu N; Matsuda J; Kaku N; Takeda K; Uno N; Kosai K; Hasegawa H; Yanagihara K
    Jpn J Infect Dis; 2018 Jul; 71(4):281-285. PubMed ID: 29709981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Verification of an Automated, Digital Dispensing Platform for At-Will Broth Microdilution-Based Antimicrobial Susceptibility Testing.
    Smith KP; Kirby JE
    J Clin Microbiol; 2016 Sep; 54(9):2288-93. PubMed ID: 27335151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of CLSI and EUCAST Cefepime breakpoint changes on the susceptibility reporting for Enterobacteriaceae.
    Bork JT; Heil EL; Leekha S; Fowler RC; Hanson ND; Majumdar A; Johnson JK
    Diagn Microbiol Infect Dis; 2017 Dec; 89(4):328-333. PubMed ID: 29031525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotypic detection of extended-spectrum beta-lactamase production in Enterobacteriaceae: review and bench guide.
    Drieux L; Brossier F; Sougakoff W; Jarlier V
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():90-103. PubMed ID: 18154532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae testing susceptible to cefepime by reference methods.
    Picão RC; Jones RN; Mendes RE; Castanheira M
    J Clin Microbiol; 2013 Jul; 51(7):2388-90. PubMed ID: 23616458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.